Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

2.1 Pembrolizumab (Keytruda, Merck Sharp & Dohme) with pemetrexed and platinum chemotherapy has a marketing authorisation for the first-line treatment of metastatic non-squamous non-small-cell lung carcinoma (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive tumour mutations.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 Pembrolizumab solution for infusion costs £2,630.00 per 100‑mg vial (excluding VAT; BNF online, accessed October 2020).

The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.